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Lymphedema is a common complication that occurs after breast cancer treatment in up to 30% of the
patients undergoing surgical lymph node excision. It is associated with tissue swelling, ﬁbrosis,
increased risk of infection, and impaired wound healing. Despite the pronounced clinical manifestations
of the disease, little is known about the morphological and functional characteristics of the lymphatic
vasculature during the course of lymphedema progression. We used an experimental murine tail
lymphedema model where sustained ﬂuid stasis was generated on disruption of lymphatic ﬂow,
resulting in chronic edema formation with ﬁbrosis and adipose tissue deposition. Morphological
analysis of the lymphatic vessels revealed a dramatic expansion during the course of the disease, with
active proliferation of lymphatic endothelial cells at the early stages of lymphedema. The lymphatic
capillaries exhibited progressively impaired tracer ﬁlling and retrograde ﬂow near the surgery site,
whereas the collecting lymphatic vessels showed a gradually decreasing contraction amplitude with
unchanged contraction frequency, leading to lymphatic contraction arrest at the later stages of the
disease. Lymphedema onset was associated with pronounced inﬁltration by immune cells, predomi-
nantly Ly6Gþ and CD4þ cells, which have been linked to impaired lymphatic vessel function.
(Am J Pathol 2016, 186: 2193e2203; http://dx.doi.org/10.1016/j.ajpath.2016.04.006)
The lymphatic vascular system has for a long time been a
rather neglected research topic, which has delayed the
appreciation of its role in cellular and physiological pro-
cesses.1 Only recently, the discovery of lymphatic-speciﬁc
genes has enabled a deeper understanding of mechanisms
that control lymphatic development, and has helped to
unravel an unanticipated role of lymphatic vessels in a
large number of pathologies, including cancer progression,
inﬂammation, and cardiovascular disease.2,3 Functional
impairment of the lymphatic system results in reduced
drainage of extravasated ﬂuid and macromolecules, leading
to a condition known as lymphedema, which most commonly
occurs in the subcutaneous space.4
Lymphedema represents a complex pathobiology, where
lymphatic insufﬁciency results in chronic ﬂuid stasis with
subsequent disruption of the normal cutaneous tissue
architecture and profound inﬂammation. More important,
lymphedema is characterized by increasing deposition of
adipose tissue and progressive tissue ﬁbrosis.5 Secondary
lymphedema represents the most common form of lymph
drainage failure in Western countries, and occurs mainly as
an iatrogenic complication after breast cancer surgery or
surgical removal of other solid tumors, such as gynecological
cancers and melanomas.6,7 The progressive swelling of the
affected limb because of lymph stagnation and ﬁbroadipose
tissue deposition leads to a feeling of heaviness, functional
impairment, sensory deﬁcits, recurrent inﬂammation and
infections, impaired wound healing, and, rarely, secondary
tumors.8,9
There is much evidence that lymphedema is a multistep
procedure where lymphatic injury merely constitutes the
initial trigger of the disease.10,11 This is supported by the
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ﬁnding that only a fraction of the patients treated surgically
for breast cancer develop lymphedema, which usually
appears months to years after the surgery, indicating that
secondary events are necessary to trigger the structural and
functional deﬁcits of this disorder, or that some patients are
more prone to develop the condition. Some patients sub-
jected to minimally invasive procedures (eg, lymph node
biopsy) may develop lymphedema as well, suggesting that
even minor lymphatic damage can initiate the pathobiologic
sequence resulting in lymphedema.
Even though lymphatic injury is considered as the initi-
ator of the pathological process, little attention has been paid
to the structural and functional alterations of the lymphatic
vasculature during lymphedema development. Lymphatic
function is mainly evaluated by lymphoscintigraphy that
provides mostly qualitative rather than quantitative results,12
whereas the quantitative evaluation of lymphatic contractile
function has been limited.13
Lymphatic vessels dynamically participate in inﬂammatory
reactions, modulate immune responses and immune tolerance,
and respond to increased ﬂuid loads in the tissue. They expand
in inﬂammation, and their activation reduces the severity of
tissue inﬂammation,14 highlighting an emerging role of the
lymphatic vasculature as a therapeutic target. Inﬂammation
also constitutes a hallmark of lymphedema in the clinic as well
as in experimental models,5,15 and it has been reported that
cyclooxygenase 2 inhibitors reduce the severity of experi-
mental secondary lymphedema, indicating a potential
involvement of inﬂammation in lymphedema development.16
Our aim was to investigate in detail the morphological
and functional changes of lymphatic vessels in response to
sustained ﬂuid stasis in a surgically induced secondary
lymphedema model. Surgical removal of a circumferential
piece of mouse tail skin, together with ablation of deep
collecting lymphatic vessels, was performed to reliably
induce tissue swelling and lymphedema. We found that
lymphedema development led to lymphatic vessel remod-
eling, with enlargement of these vessels and pronounced
proliferation of lymphatic endothelial cells at the early stage
of the disease. Functional in vivo studies using quantitative
near-infrared imaging revealed a gradual impairment of
collecting lymphatic vessel function and also a reduced
perfusion of the lymphatic capillaries. Immunoﬂuorescence
and ﬂow cytometry studies identiﬁed an increased immune
cell inﬁltration with a predominant presence of Ly6G- and
CD4-positive cells in the developing lymphedema.
Materials and Methods
Lymphedema Mouse Tail Model
Female C57BL/6J:ICR and FVB mice were kept under
conventional conditions. Surgery was performed at the age
of 8 to 12 weeks. Tail lymphedema was induced by surgery,
as previously described.17 In brief, a circumferential full-
thickness portion of skin, 3 to 4 mm, was excised 2 cm
distal to the tail base. The deep collecting lymphatic vessels,
running along the two lateral veins, were identiﬁed under a
dissecting microscope by injecting 5 to 10 mL of 1% Evans
Blue Dye into the tip of the tail. They were microsurgically
ablated, sparing the veins. Lymphedema development was
studied for up to 6 weeks after the operation. All animal
experiments were performed in accordance with animal
protocols approved by the Cantonal Veterinary Ofﬁce
Zurich (license number 225/2013).
Tail Volume Measurements and Histological Analyses
Tail volume measurements were performed weekly, using a
digital caliper, at 1-cm intervals starting distally to the sur-
gical excision site. Tail volumes were calculated using the
truncated cone formula.18 For histological analysis, a 2- to
3-mm wide tail piece was dissected distally to the surgical
excision margin and was ﬁxed in 4% paraformaldehyde.
The tissue was decalciﬁed for 7 days using 0.5 mol/L EDTA
(Sigma, St. Louis, MO), and was then embedded in parafﬁn.
Sections of 6 mm were obtained, and histological analyses
were performed on hematoxylin and eosin and picrosirius
red stained sections. Sections were stained with hematoxylin
solution (J.T. Baker, Center Valley, PA) for 3 minutes,
washed under tap water, dipped in 0.1% HCl, and stained
with eosin solution (J.T. Baker) for 1 minute. Other sections
were stained with picrosirius red solution (Sigma) for 1 hour
and then dipped in acidiﬁed water (0.5% acetic acid in
water). Sections were mounted with Eukitt medium
(Sigma).
Immunoﬂuorescence stains were performed on tail skin
embedded in OCT (Sakura Finetec, Zoeterwoude, the
Netherlands) and snap frozen in liquid nitrogen. Cryosections
(7 mm thick) were ﬁxed for 2 minutes in acetone (20C)
and 5 minutes in methanol (4C), washed in phosphate-
buffered saline (PBS), incubated with immunomix (5%
nonimmune donkey serum and 0.2% bovine serum albumin
in PBS with 0.3% Triton X) and incubated overnight (4C)
with rabbit antieLYVE-1 antibody (AngioBio, San Diego,
CA; 1:600), rat-Meca32 (BD Pharmingen, Franklin Lakes,
NJ; 1:200), or antibodies against Ki-67 (Dako, Glostrup,
Denmark; 1:200), CD45 (R&D Systems, Minneapolis, MN;
1:100), F4/80 (Abcam, Cambridge, UK; 1:200), CD68
(Abcam; 1:200), or CD206 (R&D; 1:200). The sections were
then incubated for 30 minutes with Alexa488- (1:200),
Alexa594- (1:200) or Alexa350- (1:200) conjugated sec-
ondary antibodies and Hoechst 33342 (1:1000) (all from
Invitrogen, Thermo Fischer, Waltham, MA). Some sections
were ﬁxed with 4% paraformaldehyde and then stained with
BODIPY dye 493/503 (Invitrogen; 1:1000) in Dako diluent
(Dako).
Immunoﬂuorescence stains were analyzed using an
Axioskop 2 mot plus microscope (Carl Zeiss, Oberkochen,
Germany) equipped with an Illuminator HXP 120 (V) and
an AxioCam MRc camera, and ﬁve images per tissue sec-
tion were acquired with a Plan Apochromat 10/0.45
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numerical aperture objective. Images of hematoxylin and
eosin and picrosirius red stained sections were acquired
using a Slide Scanner Panoramic 250 BF Flash (3D Histech,
Ramsey, NJ) equipped with a Brightﬁeld CIS 3CCD VCC-
F52U25CL with a 20/0.8 numerical aperture objective.
Morphometric analyses of vessels and of epidermal thick-
ness, as well as quantiﬁcation of tissue immunoﬂuorescence
stains, were performed using ImageJ software version 1.46r
(NIH, Bethesda, MD).
Light Sheet Microscopy of Tail Tissues
Mouse tail cross sections (4 to 5 mm thick) were ﬁxed for
2 hours at 4C. Samples were then permeabilized with 0.5%
Triton X-100 in PBS for 2 days, washed, and blocked with
PermBlock solution (1% bovine serum albumin, 0.1%
Tween 20) for 2 days (room temperature). Rabbit antie
LYVE-1 (AngioBio) and rat anti-CD31 antibodies were
used for staining, by incubation in PermBlock solution for 7
days at 4C under constant agitation. After multiple washing
steps in PBS with 0.1% Tween 20 for 2 days, the samples
were incubated for 7 days in PermBlock with Alexa488- and
Alexa594-conjugated antibodies at 4C (Invitrogen). Tissue
samples were then embedded in 1% ultrapure agarose gels
on ice and dehydrated in a series of methanol solutions
(50%, 70%, 95%, 100%), each step for more than an hour
with the last step overnight. Tissue clearing was achieved
with incubation in 50% benzyl alcohol/benzyl benzoate
(Acros Organics, Thermo Fischer; 1:2) for 3 to 4 days, until
the tissue was visibly clear. Samples were stored in 50%
benzyl alcohol/benzyl benzoate at 4C in the dark. Whole
mount image acquisition was performed using an Olympus
MVX10 LaVision BioTec Ultramicroscope (LaVision,
Bielefeld, Germany), and images were processed using
Imaris 7.6.4 (Bitplane).
Flow Cytometry
Mice were euthanized, and single-cell suspensions were
obtained from the full-thickness tail skin distal to the
surgical margin. The tissue was minced and incubated in
5 mg/mL collagenase II and 0.05 mg/mL DNase (both from
Sigma) in RPMI 1640 medium (Gibco, Thermo Fischer) for
30 minutes at 37C. Single-cell suspensions were ﬁltered
through 70- and 40-mm cell strainers and resuspended in
FACS buffer (2% fetal bovine serum, 2 mmol/L EDTA).
Cells were incubated with CD16/CD32 (1:100; Biolegend,
San Diego, CA) to block endogenous Fc receptors and live/
dead staining was performed using Fixable Aqua Zombie
(1:300; Invitrogen). Cell populations were analyzed using
multicolor surface markers for myeloid and lymphoid pop-
ulations. Myeloid panel: CD45 (Paciﬁc blue, 1:400), Ly6G
(ﬂuorescein isothiocyanate, 1:250), Ly6C (PE, 1:125),
CD11b (PerCPC5.5, 1:400), CD11c (PECy7, 1:400) (all
from Biolegend), and F4/80 (Alexa Fluor 647; AbD Serotec,
Oxford, UK; 1:400). Lymphocyte panel: CD45 (Paciﬁc
blue, 1:400), CD3 (PECy7, 1:200), CD4 (APC, 1:200), CD8
(ﬂuorescein isothiocyanate, 1:400) (all from Biolegend).
In Vivo Imaging of Lymphatic Vessel Function
A Zeiss StereoLumar V12 stereomicroscope adapted for
near infrared imaging (NIR) was used for lymphatic vessel
imaging.19 Using a Harvard Apparatus PHD2000 syringe
pump (Harvard Bioscience, Holliston, MA) and a custom-
made intradermal catheter consisting of PE10 tubing and a
30 g needle, two different protocols for bolus injections
were applied. For visualization of the transport function in a
region of interest near the surgical excision margin, a
controlled infusion of 5 mL of NIR dye P20D800 was per-
formed at 0.5 mL/minute for 10 minutes at a site 1 cm
proximal from the tail tip. Videos were acquired for a total
of 20 minutes. For quantiﬁcation of collecting lymphatic
vessel contractility, a bolus injection of 5 mL of P20D800
dye was performed, followed by controlled infusion of an
additional 1 mL at a rate of 0.2 mL/minute for 5 minutes,
injected 1 cm proximal from the tail tip. During the
controlled infusion, a 15-minute video recording took place
at a location 2 to 3 cm proximal to the infusion site. At the
end of the 15-minute video recording, an area ranging from
the injection site to the surgical excision margin was imaged
with serial snapshots. On the video recording, a region of
interest analysis of ﬂuorescence intensity was performed,
using Zeiss AxioVision software Vs40 version 4.8.2.0
(Zeiss, Jena, Germany) to evaluate the contractility of the
collecting lymphatic vessels.20 A custom software in Matlab
was used to analyze the frequency and amplitude of the
contractions for a period of 5 minutes (from 6 to 11 minutes
of the 15-minute video). The contraction amplitude was
expressed as a percentage of the mean signal intensity.
Statistical Analysis
All data represent means  SD. All experiments were
conducted at least in three replicates. Means of two groups
were compared with the two-tailed Student’s t-test; means
of three or more groups were analyzed with one-way anal-
ysis of variance with Tukey’s post hoc multiple comparison
test. Analyses were performed using GraphPad Prism
version 6.0 (GraphPad Software, San Diego, CA). P < 0.05
was accepted as statistically signiﬁcant.
Results
Surgical Induction of Lymphedema Results in
Fibroadipose Tissue Accumulation
We used an established mouse tail model of lymphedema,
where lymphedema was surgically induced by removal of a
circumferential portion of skin 2 cm distal to the tail base
and dissection of the collecting lymphatic vessels.21 Mice
were observed for 6 weeks postoperatively to evaluate the
Spatiotemporal Changes in Lymphedema
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course of lymphedema development. Evaluation of the tail
volume distal to the surgical incision area showed a gradual
increase that started 1 week postoperatively (1.6-fold
change versus control unoperated mice, P < 0.001) and
steadily increased until week 6 (2.4-fold change versus
control, P < 0.001) (Figure 1, A and B). Whole-tail cross
sections stained with hematoxylin and eosin revealed
several architectural changes of the edematic tails, with
increased edema, cellularity, and epidermal thickness in
comparison to unoperated tails (Figure 1C). The epidermal
thickness increased from 27.3  5.2 mm to 60.1  21.9 mm
after 4 weeks (P < 0.01) and to 51.4  9.7 mm after 6 weeks
(P < 0.05) (Figure 1F). Fibrotic tissue deposition was
assessed by quantiﬁcation of collagen using sirius red
staining, which revealed an increased collagen deposition
(1.5-fold increase compared with control tails, P < 0.05)
that began 2 weeks postoperatively with a further increase
after 4 and 6 weeks (Figure 1, D and G). Lipid accumula-
tion, evaluated with BODIPY staining, revealed lipid
deposition that was signiﬁcantly increased at 6 weeks
postoperatively (2.6-fold increase compared with control
tails, P < 0.01) (Figure 1, E and H). These results indicate
that the used mouse tail model faithfully recapitulated
several of the clinical features of lymphedema.
Lymphatic Vessel Expansion during Lymphedema
Development
We next performed an evaluation of blood and lymphatic
vessels using immunoﬂuorescence stains for Meca-32
(blood vessel marker) and LYVE-1 (lymphatic vessel
marker). No major changes of blood vascularity were found
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Figure 1 Fibroadipose tissue accumulation in
lymphedema. A: Increase of tail volume over the
course of lymphedema development. B: Repre-
sentative images of unoperated control (Ctrl), 2
weeks (w) and 6 weeks postoperative mouse tails.
C: Hematoxylin and eosin (H&E) stains of parafﬁn
tail cross sections obtained 0.5 to 1 cm distal to
the surgical excision margin. Increased tissue
edema, enlarged lymphatic vessels, and inﬂam-
mation in the operated samples. The drawn line
indicates the extent of edema formation. D: Sirius
red staining of parafﬁn tail cross sections reveals
collagen in red. Collagen deposition was evaluated
between the epidermis and the muscle fascia. E:
Cryosections (7 mm thick) of mouse tails were
stained for lipid droplets with BODIPY. F:
Epidermal thickness was quantiﬁed from H&E-
stained tail cross sections. G: Collagen quantiﬁ-
cation was performed by evaluating the collagen
deposition between the epidermis and the muscle
fascia (edematic area) in Sirius redestained
sections. H: BODIPY staining was quantiﬁed as
percentage of the total tissue (section) area.
*P < 0.05, **P < 0.01, and ***P < 0.001 versus
the control (one-way analysis of variance with
Tukey’s multiple comparison test). Scale bars: 1 cm
(B); 1 mm (C and D); 200 mm (E).
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Figure 2 Lymphatic dilation and lymphangiogenesis in lymphedema. A: Immunoﬂuorescence stains for lymphatic (Lyve-1) and blood (Meca-32) vessels of
control (Ctrl) and operated mice. Quantiﬁcation of blood vessel area (B) and lymphatic vessel area (C) during the course of lymphedema. D: Quantiﬁcation of Prox-
1þ/Lyve-1þ/Ki-67þ cells reveals proliferation of lymphatic endothelial cells at the early stage [2 weeks (w) postoperatively] of lymphedema. E: Representative
three-dimensional light sheet microscopic image illustrates the morphological changes of lymphatic vessel in lymphedema. *P < 0.05, **P < 0.01, and
***P < 0.001 versus control (one-way analysis of variance with Tukey’s multiple comparison test). Scale bars: 200 mm (A); 1 cm (E).
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during the 6 postoperative weeks (Figure 2, A and B). In
contrast, there was a profound enlargement of lymphatic
capillaries in comparison to the control unoperated mice
(Figure 2A). We found that the lymphatic vessel area
gradually increased during the course of edema develop-
ment and at 6 weeks postsurgery accounted for
13.3%  5.9% of total tissue area in comparison to
1.6%  0.7% in the control tissue (P < 0.001) (Figure 2C).
We next investigated whether the lymphatic vessel
expansion was the result of passive dilation because of ﬂuid
accumulation or if the enlargement was caused by active
proliferation of lymphatic endothelial cells. Quantitative
analysis of lymphatic endothelial cell proliferation using tri-
ple immunoﬂuorescence staining for the lymphatic markers
Lyve-1 and Prox-1 and for the proliferation marker Ki-67
identiﬁed a signiﬁcant increase (4.5%  2.9% versus
0.5%  1.1%; P < 0.01) in the percentage of Ki-67þ
lymphatic endothelial cells (Lyve-1þProx-1þ) at the early
stage (2 weeks postoperatively) of lymphedema (Figure 2D).
There was a nonsigniﬁcant trend for increased proliferation of
lymphatic endothelial cells at 4 and 6 weeks after surgery.
Visualization of the three-dimensional lymphatic vessel
architecture using light-sheet microscopy revealed profound
structural changes of the lymphatic vasculature on induction
of lymph stasis, with an enlarged and plump appearance of
the lymphatic capillaries (Figure 2E). These results indicate
that active lymphatic vessel expansion occurs during the
course of lymphedema development.
Gradual Functional Impairment of Lymphatic Collectors
and Capillaries during Lymphedema Development
To evaluate the functionality of the lymphatic vasculature
during the course of lymphedema development, we
used near-infrared intravital microscopy, as previously
described.19 Using an infusion pump and an intradermal
catheter, the lymphatic-speciﬁc tracer P20D800 was injected
close to the distal end of the tail and the uptake and transport
of the tracer through the initial and collecting lymphatic
vessel network was monitored by stereomicroscopic near-
infrared imaging. In unoperated control mice, there was a
rapid transport of the tracer toward the tail base via
lymphatic collectors and the capillary network, which
appeared with a regular pattern of honeycomb-like struc-
tures (Figure 3A and Supplemental Video S1). At 2 weeks
postoperatively, the transport of the tracer toward the tail
base was delayed and retrograde ﬂow through lymphatic
capillaries occurred close to the excision site (Supplemental
Video S2). Nonetheless, we still observed a complete ﬁlling
of the lymphatic capillaries with tracer 15 minutes after
Figure 3 Gradual impairment of lymphatic
capillary function during lymphedema develop-
ment. A: Whole tail reconstruction using snapshot
stereomicroscope images 15 minutes after injec-
tion of the near infrared imaging dye. Gradual
disappearance of the honeycomb lymphatic capil-
lary pattern during lymphedema development,
indicating decreased perfusion of the lymphatic
capillary vessels. B: Loss of the honeycomb pattern
of lymphatic capillaries and interstitial accumula-
tion of the injected dye in tail close-ups located 1
to 2 cm distal to the surgical excision margin.
Scale bars: 1 cm (A); 2 mm (B). Ctrl, control; w,
weeks.
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injection (Figure 3A). At 4 and 6 weeks after surgery, the
transport time to the incision area was further delayed and a
discontinuous uptake of the tracer into the capillary network
was observed (Figure 3A and Supplemental Video S3).
There was also an increased amount of tracer detected in the
interstitial tissue. Close-ups of control and operated tails
demonstrated the gradual loss of the perfused honeycomb
pattern of lymphatic capillaries over time in tails with
lymphedema (Figure 3B).
We next assessed the functionality of the collecting
lymphatic vessels by analyzing the contractility of these
vessels during near-infrared video acquisitions. By using a
region of interest analysis on each collecting vessel, we
were able to visualize and quantify the contraction ampli-
tude and frequency. Unoperated mice demonstrated a
regular pattern of contractions with a large amplitude
(Figure 4A and Supplemental Video S4). Starting at 2
weeks postoperatively, the amplitude was diminished but
the frequency was unaffected (Figure 4B and Supplemental
Video S5). After 4 weeks, the contraction amplitude was
even more blunted (Figure 4C and Supplemental Video S6),
and at 6 weeks after the operation, it was barely detectable
(Figure 4D and Supplemental Video S7). A quantitative
analysis revealed a signiﬁcantly reduced amplitude of the
lymphatic vessel contractions at each time point after
lymphedema induction (control: 26.7%  6.8%; 2 weeks:
12.7%  9.5%; 4 weeks: 9.8%  6.1%; 6 weeks:
5.1%  2.3%, expressed as a percentage of mean signal
intensity), whereas the frequency of the contractions did not
signiﬁcantly change during the disease progression in
comparison to unoperated controls (control: 4.5  0.1; 2
weeks: 4.0  0.6; 4 weeks: 4.1  0.7; 6 weeks: 3.7  0.6
contractions/minute) (Figure 4, E and F). The pumping
score, which was calculated by multiplying the contraction
amplitude with the contraction frequency, was 118.9  28
in unoperated mice (Figure 4G) and declined signiﬁcantly
on induction of lymphedema (2 weeks: 47.3  31.2; 4
weeks: 37.8  23.2; 6 weeks: 18.7  7.7). These results
indicate a progressive loss of function of both initial and
collecting lymphatic vessels during the development of
lymphedema in this model.
Distinct Changes in the Immune Cell Inﬁltrate in
Lymphedema
Lymphedema has been described to be associated with an
increased immune cell inﬁltrate.22 Immunoﬂuorescence
stains revealed a slight increase in the inﬁltration by CD45þ
cells at 2 weeks postoperatively, with a signiﬁcant increase
at 4 weeks and even more pronounced at 6 weeks after the
operations (control: 1.01%  0.42% of the tissue area; 2
weeks: 4.18%  1.37%; 4 weeks: 6.70%  3.58%; 6 weeks:
9.11%  1.84%). Inﬁltration by F4/80 and CD68-positive
macrophages, as well as by CD206-positive cells, reached a
peak at 4 weeks postoperatively (Figure 5). To more pre-
cisely quantify these different immune populations at the
onset of the disease, ﬂow cytometry analysis was performed
on mice 2 weeks after the operation (Figure 6). There was a
signiﬁcant increase of CD45þ cells from 0.41%  0.07% of
the total single cells in unoperated mouse tails to
2.05%  1.03% at 2 weeks postoperatively (P < 0.01)
(Figure 6A). Further analysis of other immune cells sub-
population revealed an increase of both myeloid and
lymphoid cells 2 weeks postoperatively, with Ly6Gþ and
CD4þ cells accounting for most of the inﬁltrate (Ly6Gþ:
from 0.006%  0.001% to 0.9%  0.6%, P < 0.05; CD4þ:
Figure 4 Quantitative assessment of collecting lymphatic vessel contractility of unoperated mice and of lymphedema mice at 2, 4, and 6 weeks (w) after the
surgery. A: Representative contractility pattern of nonoperated tail, showing large-amplitude contractions. B: Representative contractility pattern of tail 2 weeks
after surgery, showing preservation of contractility albeit with smaller-amplitude contractions. C: Representative contractility pattern of tail 4 weeks after surgery,
showing a further decrease in contraction amplitude. D: Representative contractility pattern of tail 6 weeks after surgery, showing only weak amplitude con-
tractions. E: Quantiﬁcation of contraction amplitudes reveals a signiﬁcant decrease at all postoperative time points. F: Quantiﬁcation of the frequency of
contractions reveals no signiﬁcant changes after induction of lymphedema. G: Quantiﬁcation of pumping score (amplitude  frequency) reveals a signiﬁcant
decrease at each postoperative time point. **P < 0.01, ***P < 0.001 (one-way analysis of variance with Tukey’s multiple comparison test). Ctrl, control.
Spatiotemporal Changes in Lymphedema
The American Journal of Pathology - ajp.amjpathol.org 2199
from 0.02%  0.008% to 0.5%  0.2% of the total single
cells; P < 0.05) (Figure 6, B and D). Monocytes (Ly6Cþ
cells), macrophages (CD11cþF4/80þ cells), and CD8þ
cells increased as well (Ly6Cþ: from 0.01%  0.005%
to 0.07%  0.03%, P < 0.05; CD11cþF4/80þ: from
0.04%  0.01% to 0.39%  0.08%, P < 0.001; CD8þ:
from 0.002%  0.001% to 0.04%  0.01%, P < 0.05)
(Figure 6, BeD). Thus, a pronounced increase in immune
cell inﬁltration was apparent in lymphedema tails at 2 weeks
after operation.
Discussion
In this study, we used a mouse tail model of lymphedema
and performed immunoﬂuorescence analyses and functional
assays to analyze the morphology and functionality of
lymphatic capillaries and collecting lymphatic vessels
during the course of the disease, as well as the immune cell
inﬁltration, with a particular focus at the early stage of
lymphedema development. We found that lymphatic vessel
morphology was profoundly altered during the course of
lymphedema development and was associated with a
gradual impairment of lymphatic vessel function and a
distinct immune cell inﬁltration.
Secondary lymphedema is a rather frequent complication
of cancer surgery and presents as a disease with complex
pathology. It primarily develops because of the insufﬁciency
of the lymphatic vasculature to drain the extravasated
interstitial ﬂuid and macromolecules. Clinically and histo-
logically, lymphedema is characterized by edema formation
manifested as swelling of the limb, epidermal thickening,
adipose tissue accumulation, and ﬁbrosis, which was
initially described in primary lymphedema23 and has been
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detected in secondary lymphedema as well.5 In our study,
we found that tail swelling and ﬁbroadipose tissue deposi-
tion were strongly induced on removal of a circumferential
portion of skin and ablation of the collecting lymphatic
vessels, thus reliably reproducing the histopathological
hallmarks of the disease.
The lymphatic vasculature is an integral, although rather
understudied, component of lymphedema development, often
concealed by the pathological manifestations of the disease.
Both dermal lymphatic hyperplasia and hypoplasia have been
reported in lymphedema patients,24,25 where it has surpris-
ingly been noted that dilation of the lymphatic capillaries
occurs even in the contralateral arm of patients experiencing
lymphedema.26 In the experimental mouse tail model, we
observed a gradual enlargement of lymphatic vessels with an
increase of the lymphatic vessel area during the course of
lymphedema development, whereas the blood vascularity
remained unchanged. Evaluation of lymphatic endothelial
cell proliferation revealed an active proliferation of these
cells, which was most prominent during the early stage of
lymphedema development (2 weeks postoperatively). This
proliferation of the lymphatic endothelial cells does not appear
to lead to sprouting lymphangiogenesis but, instead, to the
enlargement of existing lymphatic vessels, resulting in a pro-
found remodeling of the lymphatic vasculature as demon-
strated with the three-dimensional light sheet microscopy.
Similar ﬁndings have been reported in chronic inﬂammation
(eg, of the gastrointestinal tract), indicating that lymphatic
vessel expansion may represent a compensatory mechanism to
maintain interstitial ﬂuid clearance and ﬂuid homeostasis.27
When imaged through the skin surface, lymphatic capil-
laries in the mouse tail normally have a honeycomb-like
pattern.17,28 Evaluation of the lymphatic capillaries in
unoperated control mice with NIR imaging conﬁrmed the
honeycomb pattern, with rapid transport of an injected tracer
through the initial and collecting lymphatic vessels toward
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the tail base. Surgical induction of lymphedema, however,
resulted in a gradual impairment of lymphatic capillary
function, identiﬁed as the loss of the intact honeycomb-like
pattern and increased evidence of retrograde ﬂow, particu-
larly in close proximity to the surgical excision site.
Although it remains a technical challenge to accurately mea-
sure pressure within lymphatic vessels in mice, increases in
intralymphatic pressure, which have previously been reported
within lymphatic capillaries in human primary lymphedema,
are likely also present in our model and thus could inhibit the
efﬁcient ﬁlling of these vessels with the injected tracer.29
These ﬁndings suggest that interstitial ﬂuid accumulation
causes edema, leading to lymphatic vessel remodeling, which
compromises the function of the lymphatic capillaries.
We also examined the functionality of the collecting
lymphatic vessels by evaluating their contractility using
noninvasive NIR imaging. Previous studies have reported a
reduced frequency of contractions in experimental models
of inﬂammation and cancer.19,30 Despite the absence
of comprehensive clinical studies, two clinical reports of
lymphedema patients have shown reduced contractility of
lymphatic vessels and a negative correlation between the
pressure generated by the lymphatic pump and the degree of
swelling.13,25 In accordance with these clinical observations,
our study demonstrates, for the ﬁrst time, a gradual decrease
of the collecting lymphatic vessel contractility during pro-
gression of lymphedema in an animal model. Signiﬁcant
decreases in contractile amplitude were seen already at 2
weeks postoperatively, and led to an almost complete
lymphatic vessel arrest at the later stages of lymphedema.
More important, unlike in other inﬂammatory condi-
tions,19,31 reduced lymphatic vessel contractile amplitude/
strength was observed in lymphedema rather than a reduc-
tion in the frequency of contractions.
The peripheral lymphatic system regulates tissue ﬂuid
homeostasis and also directs the transport of immune cells.
It has been unclear for a long time how the lymphatic
vasculature is affected by inﬂammation. However, several
recent studies have revealed that inﬂammation leads to
lymphatic vessel expansion, with lymphatic hyperplasia and
lymphangiogenesis in several inﬂammatory conditions, both
in patients and in experimental models.32 It has also been
found that inﬂammation is associated with impaired
lymphatic drainage, particularly in chronic inﬂammatory
conditions.30,33,34 Lymphedema shows pronounced inﬂam-
matory manifestations,22 but whether tissue inﬂammation is
a consequence of or an active contributor to lymphatic
vascular insufﬁciency has not been studied in much detail.
It has been suggested that inﬁltration of nitric oxidee
producing CD11bþGr1þ cells on oxazolone skin sensitiza-
tion might modulate the microenvironment surrounding the
collecting lymphatic vessels, thus impairing lymphatic
contractility.35 Similarly, CD11bþ cells have been reported
to contribute to reduced lymphatic contractility.31,33 In our
study, we identiﬁed signiﬁcantly increased populations of
CD11bþLy6Gþ cells, a subgroup of CD11bþGr1þ cells,
and CD4þ immune cells in the affected tissue 2 weeks
postoperatively, a time point that coincides with the onset of
the lymphatic vessel contractility decrease. It has been re-
ported that depletion of CD4þ cells leads to improved
lymphatic function in a murine lymphedema model.36
However, in another study in which all CD11bþ cells
were depleted in a lymphedema model,37 no change in
swelling or inﬂammation occurred. Thus, it is conceivable
that a global CD11bþ cell depletion results in elimination
of both harmful and beneﬁcial players in lymphedema
progression. For example, macrophages may support lym-
phangiogenesis,38,39 and their depletion might counterbal-
ance the depletion of adverse immune cell subsets.
Together, our data reveal, for the ﬁrst time, an active role
of the lymphatic vasculature in lymphedema development,
indicating that monitoring of lymphatic transport function
might serve as a clinical parameter to evaluate the disease
onset/progression in postcancer surgery patients. The
increased presence of speciﬁc immune cell populations at
the early stages of lymphedema may offer insights into the
pathobiology of the disease, which will have to be further
studied, because they may constitute potential therapeutic
targets to ameliorate lymphedema.
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